Vicapsys Life Sciences, Inc.
VICP
Rank in Stocks
#26887
Vicapsys Life Sciences, Inc. is primarily focused on bringing its exclusive... Vicapsys Life Sciences, Inc. is primarily focused on bringing its exclusive VICAPSYN product to market, guiding it through development and commercialization. This product's intended application is within the field of transplantation, specifically for various transplant therapies and associated stem-cell uses. Additionally, the company is advancing the development of VYBRIN, a compound based on CXCL12. VYBRIN is being investigated for multiple purposes: preventing the formation of post-surgical adhesions following abdominal operations, coating implantable medical devices and other implants to inhibit fibrosis, and promoting wound healing, with a particular emphasis on diabetic ulcers. The firm, originally incorporated in 1997, transitioned its name from Phage Therapeutics International, Inc. to Vicapsys Life Sciences, Inc. in September 2017. Its operations are headquartered in Suwanee, Georgia.
Share Price
$0.5
Last synced: 2026-11-09
Market Cap
$17.69M
Change (1 day)
0.00%
Change (1 year)
-66.67%
Country
Stock data: Financial Modeling PrepΒ·Updated Β·Not investment adviceΒ·How we calculate this
Trade Vicapsys Life Sciences, Inc. (VICP)
Category
Healthcare
EPS for Vicapsys Life Sciences, Inc. (VICP)
EPS as of March 2026 TTM: $0.00
According to Vicapsys Life Sciences, Inc.'s latest financial reports, its current EPS (TTM) is $0.00. At the end of 2025 the company had an EPS of $-0.02, an increase over its 2024 EPS of $-0.03.
EPS history for Vicapsys Life Sciences, Inc. from 2008 to 2026
EPS at the end of each year
| Year | EPS | Change |
|---|---|---|
| 2026 (TTM) | 0.00 | -85.00% |
| 2025 | $-0.02 | -32.29% |
| 2024 | $-0.03 | -15.79% |
| 2023 | $-0.03 | 5.88% |
| 2022 | $-0.03 | 141.04% |
| 2021 | $-0.01 | -69.41% |
| 2020 | $-0.04 | -63.50% |
| 2019 | $-0.12 | -47.83% |
| 2018 | $-0.23 | -57.41% |
| 2017 | $-0.54 | -88.80% |
| 2009 | $-4.82 | -32.68% |
| 2008 | $-7.16 | 0.00% |
EPS for similar companies or competitors
| Company | EPS | EPS Difference | Country |
|---|---|---|---|
| $15.66 | -522,100.00% |
US
|
|
| $-7.07 | 235,566.67% |
US
|
|
| $-5.29 | 176,233.33% |
AU
|
|
| $12.88 | -429,436.67% |
BE
|
|
| $21.56 | -718,766.67% |
NL
|
Questions about Vicapsys Life Sciences, Inc.'s earnings per share (EPS)
What is Vicapsys Life Sciences, Inc.'s earnings per share (EPS)?
Vicapsys Life Sciences, Inc.'s earnings per share (EPS) over the last twelve months is $0.00, as of Mar 2026.
What was Vicapsys Life Sciences, Inc.'s earnings per share (EPS) in 2025?
In 2025, Vicapsys Life Sciences, Inc.'s earnings per share (EPS) was $-0.02, compared with $-0.03 in 2024.
How has Vicapsys Life Sciences, Inc.'s earnings per share (EPS) changed since 2020?
From 2020 to 2025, Vicapsys Life Sciences, Inc.'s earnings per share (EPS) was highest in 2021 ($-0.01) and lowest in 2020 ($-0.04).
How does Vicapsys Life Sciences, Inc.'s earnings per share (EPS) compare with similar companies?
Vicapsys Life Sciences, Inc.'s earnings per share (EPS) ($0.00) is higher than that of 2 of the 5 similar companies listed above. The highest among them is Argenx SE, with $21.56.